Biomarkers and Diagnostics World Congress
Visit Q2 Solutions Booth #10, meet our Biomakers and Companion Diagnostic Experts and attend our Podium Presentation.
About This Event
We will be conducting a podium presentation on Companion Diagnostics and Biomarkers for Cancer Immunotherapy. Come see our scientists speak or visit us at Booth #10 to learn more about how we can help you with you biomarker and companion diagnostics needs.
Attend our presentation to learn about our cancer immunotherapy expertise. We offer comprehensive genomic and biomarker discovery and development expertise, scientific acumen, data informatics and clinical trial operational excellence. How can we help you?
2016 Q2 Solutions’ Podium Presentation Details
Session: Diagnostics to guide cancer immunotherapy
Date and time: Wednesday, May18, 2016 | 2:50pm-3:20pm | Tracks 4 and 6
Title: From eligibility to CDx: developing and implementing effective biomarker strategies for Immuno-oncology trials
Abstract: By capitalizing on fundamental cancer and immunology research, Immuno-Oncology (I-O) has led to exciting breakthroughs. A deep understanding of the tumor and the anti-tumor immune response is needed to fully exploit this strategy, requiring a fresh perspective on biomarker strategies and a comprehensive toolkit for biomarker testing. I-O trials face particular challenges, and we will discuss how we have engaged Pharma and focused critical tools—anatomic pathology, flow cytometry, and genomics—on these challenges, as well as how we have leveraged this knowledge to facilitate transitioning to companion diagnostic development.
Even if you are not able to attend the event, you can register to receive a copy of our presentation after the Biomarkers and Diagnostics World Congress 2016.
Not registered for the conference? Go to the conference website to register.
Chief Scientific Officer
Patrice Hugo, Ph.D. is chief scientific officer of Q2 Solutions, a Quintiles Quest Joint Venture. Dr. Hugo leads the organization’s global scientific strategy and implementation, developing and accelerating strategies to help improve human health through innovation that transforms science and data into actionable medical insights.
Dr. Hugo brings more than 25 years of senior scientific leadership experience with extensive management expertise in laboratory operations applied to diagnostics, therapeutic targets and clinical trials. Most recently, Dr. Hugo was Associate Vice President and Chief Scientist at Laboratory Corporation of America (LabCorp). He has held several other senior leadership positions at companies including LabCorp, Clearstone Central Laboratories, Caprion and PROCREA BioSciences. A noted industry expert, Dr. Hugo has more than 75 scientific publications in internationally renowned journals. He also is active in a number of industry organizations, including his role on the Board of Directors for the non-for-profit Personalized Medicine Partnership for Cancer in Quebec, Warnex offering analytical and bioanalytical services and his role as a Steering Committee Member for the Biomarker Factory.
Dr. Hugo obtained his Ph.D. at McGill University and completed five years of post- doctoral fellowship at the Walter Elisa Hall Institute in Australia, and Howard Hughes Medical Institute in Denver, Colorado.
Senior Director and Global Head, Translational Genomics
Patrick Hurban, Ph.D. is senior director and global head of Translational Genomics at Q2 Solutions. In this role, he is responsible for the identification and implementation of new genomic capabilities, encompassing bioinformatics and wet-laboratory methods, as well as the development and validation of genomic assays to support research and clinical programs. These include broad-based screening assays, such as exome and RNA sequencing, to highly focused expression, genotyping and sequencing assay panels that target a smaller number of genes.
Dr. Hurban has more than 25 years of experience in molecular genetics, including more than 18 years in positions of increasing responsibility in high-profile genomics-focused organizations. His research interests have focused on the genetic control of gene expression and have spanned diverse fields such as toxicology, developmental, and cancer biology.
Following a Bachelor’s degree in Biology from the University of North Carolina at Chapel Hill, he earned his Ph.D. in Human Genetics from the University of Utah in Salt Lake City before serving as a postdoctoral research fellow of the American Cancer Society in the Department of Developmental Biology at Stanford University.